*This is not financial advice. All content should be considered opinionated. We are not responsible for any of your gains and losses. I am neither a licensed nor registered financial expert. Please see a financial advisor before making investment decisions.

*This is not financial advice. All content should be considered opinionated. We are not responsible for any of your gains and losses. I am neither a licensed nor registered financial expert. Please see a financial advisor before making investment decisions.

Antares Pharma is one expensive stock. But being in the healthcare sector and a small-cap, how great is this stock and what opportunity does it provide for investors?

Let’s find out.

First, the company has impressive revenue growth! Overall revenue increased 42% YoY and they’ve achieved record revenue overall. A sign that it’s a growth stock.

It’s flagship drug, XYOSTED, continues to garner huge growth.

EpiPens are a product in huge demand and are really expensive. Selling the pens as a generic version of the EpiPen makes this company unique in its own way.

To give more background on what Antares Pharma does with Teva, it basically gives the devices for those drugs. And we’re talking about the devices used to distribute the drug.

And the company continues to do more and more business deals.

Overall, the business goes like this: As revenue increases, losses decrease. 

That shows that Antares Pharma is experiencing the benefits of economies of scale. Plus, the company is profitable. Though Antares Pharma has a PE of 414.49, which is quite pricey, the company has been not only growing impressively but has also shown that it can make a profit. The company has proprietary delivery technology so if ever their biotech division struggles, then the company can rely on its medical devices division. 

Its delivery technology is in high demand by many pharmaceutical businesses. For me, this is the center of my bull thesis because the company can make a huge business off of its delivery technology business. For others, they're betting the success of its clinical trials. Overall, the company has many great things to look forward to. 

When looking at the stock chart for Antares Pharma, it's interesting to see that in the long run, the company has an inverse head and shoulders formation. People who are technical analysts will say that it's a really bullish sign. With the fundamentals making the company a bullish bet as well as its technicals, it's understandable why many investors would be bullish on the company's stock.